Please ensure Javascript is enabled for purposes of website accessibility

Why Snap, Kemet, and Iovance Biotherapeutics Jumped Today

By Dan Caplinger - May 16, 2019 at 4:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news gave these stocks even better gains than the overall market.

Thursday was another good day for the stock market, as investors generally reacted favorably to prospects that economic conditions could allow for a reversal of recent interest rate increases in the U.S. in the near future. Action taken to keep U.S. companies from using technology from national security threats, which would include Chinese telecom giant Huawei, didn't have the same negative effect as other, broader trade-related measures that the White House has used against China recently. Moreover, positive news from several key companies resulted in extraordinary share-price gains. Snap (SNAP 0.26%), Kemet (KEM), and Iovance Biotherapeutics (IOVA 3.21%) were among the top performers. Here's why they did so well.

Snap faces one less threat

Shares of Snap picked up 7% after the social media company benefited from the moves of one of its rivals. Facebook (FB 1.18%) decided that it would discontinue its Direct app for use in direct messaging with its Instagram platform, instead integrating some of the tools that Direct had into Instagram itself. Direct was seen as a competitor to the Snapchat app, and so Facebook's decision not to develop it further essentially cedes its claim to that portion of the social media market. Snap still faces larger threats from Facebook and other players in the industry, but at least for today, shareholders are pleased that Snapchat has won this battle.

White cartoon ghost holding smartphone and handbag against a yellow background.

Image source: Snap.

Kemet powers up

Kemet's stock jumped over 16% after the supplier of electronic components reported its preliminary fiscal fourth-quarter results. Revenue climbed 12%, resulting in adjusted net income more than doubling from year-ago levels. Kemet CEO Bill Lowe pointed to the success of structural changes to the company's business, as well as smart strategic acquisitions that have broadened its scope and created synergies with legacy operations. Having come off a somewhat weaker quarter three months ago, Kemet's solid gains today appear to be restoring confidence in its longer-term prospects.

Iovance advances

Finally, shares of Iovance Biotherapeutics soared 36%. The biotech reported favorable results from clinical programs, including one study of cervical cancer patients and another addressing patients with advanced metastatic melanoma. The study of the candidate treatment LN-145 showed more than triple the objective response rate as a competing cervical cancer drug, while another study of LN-144 for melanoma confirmed encouraging objective response rates of 38%. The results confirm the promise of tumor-infiltrating lymphocyte technology, and patients and investors alike hope that the news will continue to be good for Iovance.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

KEMET Corporation Stock Quote
KEMET Corporation
Snap Inc. Stock Quote
Snap Inc.
$23.26 (0.26%) $0.06
Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
$15.43 (3.21%) $0.48
Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
$193.54 (1.18%) $2.25

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.